

SH3GLB1 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a full length recombinant SH3GLB1. Catalog # AT3875a

Product Information

Application	WB, IHC, E
Primary Accession	<u>Q9Y371</u>
Other Accession	<u>BC007455</u>
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG1 kappa
Clone Names	1B3-A5
Calculated MW	40796

Additional Information

Gene ID	51100
Other Names	Endophilin-B1, Bax-interacting factor 1, Bif-1, SH3 domain-containing GRB2-like protein B1, SH3GLB1, KIAA0491
Target/Specificity	SH3GLB1 (AAH07455, 1 a.a. ~ 365 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IHC~~1:100~500 E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	SH3GLB1 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

References

GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. Yang J, et al. J Cell Sci, 2010 Mar 15. PMID 20159967.Bax activates endophilin B1 oligomerization and lipid membrane vesiculation. Rostovtseva TK, et al. J Biol Chem, 2009 Dec 4. PMID 19805544.Somatic mutation of pro-cell death Bif-1 gene is rare in common human cancers. Kim MS, et al. APMIS, 2008 Oct. PMID 19132989.Bif-1 and Bax expression in cutaneous Merkel cell carcinoma. Schlauder SM, et al. J Cutan Pathol, 2009 Jan. PMID 19125733.Endophilin B1/Bif-1 stimulates BAX activation independently from its capacity to produce large scale membrane morphological rearrangements. Etxebarria A, et al. J Biol Chem, 2009 Feb 13. PMID 19074440.





Immunoperoxidase of monoclonal antibody to SH3GLB1 on formalin-fixed paraffin-embedded human tonsil tissue. [antibody concentration 3 ug/ml]

Detection limit for recombinant GST tagged SH3GLB1 is approximately 0.3ng/ml as a capture antibody.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.